journal article·2022-03Open access

Combination of photothermal, prodrug and tumor cell camouflage technologies for triple-negative breast cancer treatment

Lirong Zhang, Xiaodong Ma, Wenhui Zhou, Qiwei Wu, Jiaqi Yan, Xiaoyu Xu, Bhawana Ghimire, Jessica M. Rosenholm, Jing Feng, Dongqing Wang, Hongbo Zhang

Abstract

Triple-negative breast cancer (TNBC) remains the most challenging breast cancer subtype. In the presented work, we have combined several emerging technologies to build up a nanoplatform for TNBC treatment: photothermal therapy, prodrug design and tumor cell camouflage formulation. First, we synthesized a paclitaxel (PTX) based prodrug PTX-SS, and then conjugated it to the surface of gold nanorod (Au NR) @ mesoporous silica (MSN) core-shell nanoparticles ([email protected]2 NPs). Subsequently, doxorubicin (DOX) was loaded into the [email protected] NPs and further coated with cell membranes isolated from MDA-MB-231 cells to form cell camouflaged [email protected]/[email protected] NPs. The [email protected]/[email protected] NPs exhibited very good DOX loading capacity and the prodrug strategy enabled the precise adjustability of PTX-SS loading to achieve the optimized ratio between PTX and DOX to maximize the synergistic effect of these two drugs, as well as enabled GSH-responsive intracellular drug release. More interestingly, the cell membrane coating not only protected the drug from premature release, but also significantly improved the targeting ability of NPs to breast cancer MDA-MB-231 cells. The NPs also showed good photothermal responsiveness with clear improvement in inhibiting MDA-MB-231 cell proliferation under laser irradiation. The in vivo studies further confirmed the effectiveness of [email protected]/[email protected] NPs on TNBC tumor inhibition in 4T1 cell grafted tumor mice model.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Extracellular vesicles in disease · Gold and Silver Nanoparticles Synthesis and Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (38)

Show source-provided references
1. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease10.1038/nrclinonc.2016.66 ↗
2. Triple-negative breast cancer molecular subtyping and treatment progress10.1186/s13058-020-01296-5 ↗
3. Bioactive nanotherapeutic trends to combat triple negative breast cancer
4. Cell membrane-coated nanosized active targeted drug delivery systems homing to tumor cells: a review10.1016/j.msec.2019.110298 ↗
5. Cancer-cell-membrane-coated nanoparticles with a yolk-shell structure augment cancer chemotherapy10.1021/acs.nanolett.9b03817 ↗
6. Cancer-cell-biomimetic nanoparticles for targeted therapy of homotypic tumors10.1002/adma.201602173 ↗
7. Prodrugs: design and clinical applications10.1038/nrd2468 ↗
8. The expanding role of prodrugs in contemporary drug design and development10.1038/nrd.2018.46 ↗
9. Prodrugs in medicinal chemistry and enzyme prodrug therapies10.1016/j.addr.2017.06.013 ↗
10. Supramolecular prodrugs based on host-guest interactions10.1039/C9CS00622B ↗
11. Albumin-binding prodrugs via reversible iminoboronate forming nanoparticles for cancer drug delivery10.1016/j.jconrel.2020.12.035 ↗
12. Novel prodrugs of decitabine with greater metabolic stability and less toxicity10.1186/s13148-019-0709-y ↗
13. Stimuli-responsive polymer-prodrug hybrid nanoplatform for multistage siRNA delivery and combination cancer therapy10.1021/acs.nanolett.9b01660 ↗
14. A novel bioengineered miR-127 prodrug suppresses the growth and metastatic potential of triple-negative breast cancer cells10.1158/0008-5472.CAN-19-0656 ↗
15. The novel platinum(IV) prodrug with self-assembly property and structure-transformable character against triple-negative breast cancer10.1016/j.biomaterials.2019.119751 ↗
16. Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer10.1039/C8CS00618K ↗
17. Clinical development and potential of photothermal and photodynamic therapies for cancer10.1038/s41571-020-0410-2 ↗
18. Understanding and advancement in gold nanoparticle targeted photothermal therapy of cancer10.1016/j.bbcan.2021.188532 ↗
19. Golden touch of the nanoparticles10.1038/s41565-020-0740-3 ↗
20. Gold nanoparticles in nanomedicine: preparations, imaging, diagnostics, therapies and toxicity10.1039/b806051g ↗
21. I. Mijakovic, gold nanoparticles in diagnostics and therapeutics for human cancer10.3390/ijms19071979 ↗
22. Mesoporous silica nanoparticles for drug and gene delivery10.1016/j.apsb.2018.01.007 ↗
23. Functionalized mesoporous silica nanoparticles in anticancer therapeutics10.1016/j.semcancer.2019.08.022 ↗
24. Mesoporous silica as a versatile platform for cancer immunotherapy
25. Janus gold nanostars-mesoporous silica nanoparticles for NIR-light-triggered drug delivery10.1002/chem.201900750 ↗
26. Hydrogel-encapsulated mesoporous silica-coated gold nanoshells for smart drug delivery
27. Gold nanostars coated with mesoporous silica are effective and nontoxic photothermal agents capable of gate keeping and laser-induced drug release10.1021/acsami.8b08395 ↗
28. Virus-sized gold nanorods: plasmonic particles for biology10.1021/acs.accounts.9b00288 ↗
29. Host-guest complexation-mediated codelivery of anticancer drug and photosensitizer for cancer photochemotherapy10.1073/pnas.1902029116 ↗
30. Cell penetrating peptides: a versatile vector for co-delivery of drug and genes in cancer10.1016/j.jconrel.2020.11.028 ↗
31. Co-delivery of curcumin and paclitaxel by “Core-Shell” targeting amphiphilic copolymer to reverse resistance in the treatment of ovarian cancer10.2147/IJN.S224579 ↗
32. Engineered exosomes for targeted co-delivery of miR-21 inhibitor and chemotherapeutics to reverse drug resistance in colon cancer10.1186/s12951-019-0563-2 ↗
33. Microfluidics based manufacture of liposomes simultaneously entrapping hydrophilic and lipophilic drugs10.1016/j.ijpharm.2016.09.027 ↗
34. Fabrication of a pH/redox-triggered mesoporous silica-based nanoparticle with microfluidics for anticancer drugs doxorubicin and paclitaxel codelivery10.1021/acsabm.9b01111 ↗
35. Thermochemotherapy: synergism between hyperthermia (42-43 degrees) and adriamycin (of bleomycin) in mammalian cell inactivation10.1073/pnas.72.3.937 ↗
36. Fabrication of redox-responsive doxorubicin and paclitaxel prodrug nanoparticles with microfluidics for selective cancer therapy10.1039/C8BM01333K ↗
37. Delivery of therapeutic oligonucleotides in nanoscale
38. Cardioprotective effects of curcumin-loaded magnetic hydrogel nanocomposite (nanocurcumin) against doxorubicin-induced cardiac toxicity in rat cardiomyocyte cell lines10.1080/21691401.2016.1261033 ↗